Progressive drug licensing: an opportunity to achieve transparency and accountability?
Wright
James M
JM
Department of Medicine, University Hospital, UBC Site, Vancouver, BC.
D002170:Canada; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D003657:Decision Making; D004341:Drug Evaluation / Q000592:standards; D004348:Drug Labeling; D004335:Drug and Narcotic Control / Q000458:organization & administration*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008004:Licensure; D011358:Product Surveillance, Postmarketing; D012941:Social Responsibility
D052246:Cyclooxygenase 2 Inhibitors; D005765:Gastrointestinal Agents; D007211:Indoles; C105050:tegaserod